Cuprina Holdings saw its stock climb 50% after announcing that a subsidiary secured 510(k) clearance from the U.S. Food and Drug Administration for MEDIFLY Maggots, a medical-grade product composed of Lucilia cuprina larvae intended for maggot debridement therapy.
The FDA authorization permits use of MEDIFLY Maggots to debride non-healing necrotic skin and soft tissue wounds. Indications listed by the company include pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds. The product is a prescription treatment and is applied under the supervision of healthcare professionals to remove dead or infected tissue.
According to the company, MEDIFLY Maggots is the first maggot debridement product cleared in the U.S. that uses the Lucilia cuprina species. Cuprina said the 510(k) clearance was granted on the basis of substantial equivalence to Medical Maggots, a product made from Lucilia sericata that previously received FDA clearance in 2004.
With this clearance, Cuprina now holds U.S. FDA commercial rights to both maggot species used in maggot debridement therapy. The company is the licensed producer and distributor of Medical Maggots for the U.S. market and, separately, holds its own clearance for MEDIFLY Maggots.
Cuprina highlighted the public health context for the therapy, noting that chronic non-healing wounds affect an estimated 1-2% of the population in developed countries. The company said that, following FDA clearance, MEDIFLY Maggots should become available to wound-care providers across the United States.
The regulatory review was conducted by the FDA's Center for Biologics Evaluation and Research, which took regulatory responsibility for medicinal maggots in December 2024. Cuprina also indicated that the U.S. clearance could help expedite registration pathways for MEDIFLY Maggots in other jurisdictions, naming Saudi Arabia, Hong Kong and mainland China as potential markets, while noting that any such registrations remain subject to local regulatory requirements.
Context for market participants
The FDA 510(k) clearance represents a formal authorization that should enable commercial distribution of MEDIFLY Maggots in the U.S. under prescription and clinical supervision. The decision confirms the company's assertion of substantial equivalence to an earlier-cleared maggot product, expanding Cuprina's portfolio of U.S. rights across two maggot species.
Investors and healthcare stakeholders should note that broader availability beyond the United States will depend on separate, local regulatory approvals. The company has framed the clearance as potentially beneficial to international registration efforts, but outcomes in those markets are contingent on the applicable authorities and processes.